Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treg cell infusion for steroid-refractory acute graft-versus-host disease after haploidentical HSCT
IRCT20230801058996N8Phase 2Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous regulatory T-lymphocytes in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Adverse effects of Treg cell therapy and Response to treatment. Started Dec 2025; status: recruiting.
02
Drugs
autologous regulatory T-lymphocytes
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on IRCT20230801058996N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230801058996N8.